Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 16.66$. Average daily volumn in 3 months 636.46k. Market cap 14.93B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 15.21$. Total volume : 755.64k. Market state PRE
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
15.21$
Change
-0.36
Volume
755.64k

Previous Close15.57
Open15.42
Day Range15.18-15.70
Bid14.83 x 800
Ask16.04 x 800
Volume755.64k
Average Volume636.46k
Market Cap14.93B
BetaN/A
52 Week Range14.81-20.49
Trailing P/E33.80
Foward P/E10.07
Dividend (Yield %)6.00%
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2020 were 5.34B an increase(0%) over the years 2019 revenue that were of 5.1B. In 2020 the company's total earnings were 618.55M while total earnings in 2019 were 625.15M(-1.12%).


Loading ...



Organization

Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.

Grifols, S.A._logo

Market Cap:
14.93B
Revenue:
5.34B
Total Assets:
15.27B
Total Cash:
579.65M


News about "Grifols, S.A."

Grifols S.A. (GRFS) upgraded Issued by Wall Street Gurus

Grifols S.A. (NASDAQ:GRFS) went up by 1.76% from its latest closing price compared to the recent 1-year high of $20.49. The company’s stock price has collected 2.77% of gains in the last five trading ...

Source from : newsheater - 3 days ago


Here’s How Your Trade Grifols S.A. (GRFS) Aggressively Right Now

Grifols S.A. (NASDAQ:GRFS) went down by -0.13% from its latest closing price compared to the recent 1-year high of $20.49. The company’s stock price has collected -3.47% of loss in the last five ...

Source from : newsheater - 11 days ago


Tag: Grifols S.A.

Grifols S.A. (NASDAQ:GRFS) at last check was buoying at $15.58 on Thursday, July 29, with a rise of 1.83% from its closing price on previous ...

Source from : stocksregister - 3 days ago


Grifols further expands its activity in Africa

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services ...

Source from : BusinessGhana - 12 days ago


Plasma Fractionation Market continues to expand with Grifols S.A. acquiring GC Pharma’s plasma fractionation facility

Thus, these factors can augment growth of the plasma fractionation market. Recently, in July 2020, Grifols S.A., a Spanish plasma-derived medicines company, acquired GC Pharma’s plasma ...

Source from : openpr.com - 5 days ago


Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the ...

Source from : Yahoo - 5 days ago


Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...

Source from : PR Newswire - 14 days ago


No Longer Able To Cross The Border, Some Former Plasma Donors Can't Get Their 2nd Vaccine Dose_image

No Longer Able To Cross The Border, Some Former Plasma Donors Can't Get Their 2nd Vaccine Dose

For many former nonimmigrant blood plasma donors, the lack of support from their former donation centers in the United States is keeping them from being fully vaccinated.

Source from : Texas Public Radio - 13 days ago


Moving Average Crossover Alert: Grifols (GRFS)

Grifols, S.A. GRFS could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ...

Source from : Yahoo Finance - 19 days ago


Grifols: Q2 Earnings Snapshot

Grifols SA (GRFS) on Thursday reported earnings of $164.9 million in its second quarter. The Barcelona, Spain-based company said it had profit of 24 cents per share. Earnings, adjusted for ...

Source from : My San Antonio - 2 days ago


There's a national plasma shortage - here's how you can help_image

There's a national plasma shortage - here's how you can help

Since the start of the COVID-19 pandemic, there has been a great need for plasma. Those who have serious cases of COVID-19 can benefit from plasma-and in some cases it can save their life.

Source from : WTHI-TV - 4 days ago


GRFS - Grifols, S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic ...

Source from : Seeking Alpha - 18 days ago


Grifols SA earnings preview: what Wall Street is expecting

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net Grifols SA is reporting latest earnings on July 29. Analysts on Wall Street expect Grifols SA ...

Source from : Business Insider - 6 days ago


Grifols, S.A. American Depositary Shares (GRFS)

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Source from : Nasdaq - 11 month ago


GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...

Source from : Benzinga.com - 19 days ago


The MX Q&A: Timothy Still, Accumetrics

On the business front Still and his team have been pursuing international sales partnerships. Accumetrics signed agreements in September 2009 with Grifols S.A. for exclusive distribution of the ...

Source from : MD&M East - 5 days ago


Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit

MADRID (Reuters) - Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in ...

Source from : MSN - 1 month ago


Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...

Source from : Yahoo Finance - 5 days ago


Moving Average Crossover Alert: Grifols (GRFS)

Grifols, S.A. GRFS could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for GRFS ...

Source from : Yahoo Finance - 19 days ago


Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria

To be constructed by Grifols Engineering, a global standard-bearer in the development and building of advanced production facilities for the healthcare and biotechnology industries When completed ...

Source from : Insurancenewsnet.com - 14 days ago


Primary Immunodeficiency Market Report 2021-2031: Visiongain Research Inc.

Other companies profiled in the report include: Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc., Biotest AG, Sanquin, and LFB SA Some of the key developments are listed below ...

Source from : Benzinga.com - 5 days ago


Automated Compounding Systems Market

According to the latest study on 'Automated Compounding Systems Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Product Type and End User'. The global automated compounding ...

Source from : openpr.com - 6 days ago


Global Parenteral Nutrition Market Share to record 5.5% CAGR through 2027

Selbyville, Delaware, According to the research report titled 'Global Parenteral Nutrition Market Size study, by Nutrient Type and Regional Forecasts 2021-2027', available with Market Study Report LLC ...

Source from : MarketWatch - 7 days ago


Immunohematology Market to Witness Elevated Growth during the Assessment Period: 2021-2030

MarketResearch.Biz –:The latest research report that completely centers “Global Immunohematology Market” is an intensive analysis of propulsive forces & risks, business opportunities, Immunohematology ...

Source from : Digital Journal - 6 days ago


Europe Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis - ResearchAndMarkets.com

and Grifols, S.A. are among the players operating in the market in this region. Key Topics Covered: 1. Introduction ...

Source from : Business Wire - 12 days ago


Europe Anticoagulant Reversal Drug Market Report 2021-2027: Market Opportunities with Increasing Research Activities on Anticoagulant Reversal Drugs

and Grifols, S.A. are among the players operating in the market in this region. Key Topics Covered: 1. Introduction Motley Fool ...

Source from : Yahoo Finance - 13 days ago


Parenteral Nutrition Market is projected to Witness Healthy Growth; Europe Region remains one of the Leading Markets 2020-2025_image

Parenteral Nutrition Market is projected to Witness Healthy Growth; Europe Region remains one of the Leading Markets 2020-2025

Get a Sample Report “Parenteral Nutrition Market” to 2025 @ The segmentation analysis of the industry with market size forecast and trends are offered in the report. The data is validated through ...

Source from : manometcurrent.com - 5 days ago


Global Cell Surface Markers Market to Reach $1 Billion by 2026

Companies: 70 - Players covered include Abbott Laboratories, Inc.; BD Biosciences; Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Grifols ...

Source from : WFMZ-TV - 1 month ago


Primary Immunodeficiency Market Report 2021-2031: Visiongain Research Inc.

Other companies profiled in the report include: Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc., Biotest AG, Sanquin, and LFB SA Some of the key developments are listed below: In ...

Source from : Yahoo Finance - 5 days ago


Outlook on the Pulmonary Drugs Global Market to 2026 - Rising Prevalence of Pulmonary Diseases is Driving Growth

11.3 F. Hoffmann-La Roche Ltd. 11.4 GlaxoSmithKline PLC 11.5 Grifols, S.A. 11.6 Merck & Co., Inc. 11.7 Pfizer Inc. 11.8 Regeneron Pharmaceuticals, Inc. 11.9 Sumitomo ...

Source from : WFMZ-TV - 26 days ago


COVID-19 Tied to Acceleration of Alzheimer's Pathology_image

COVID-19 Tied to Acceleration of Alzheimer's Pathology

Researchers found higher levels of neurofilament light and other markers of brain injury in COVID patients with neurologic symptoms compared to COVID patients without neurologic symptoms.

Source from : Medscape - 2 days ago


COVID-19 Vaccine and Guillain-Barré Syndrome: Let's Not Leap to Associations

A worldwide mass vaccination campaign to control the COVID-19 pandemic is imminent. Understanding the epidemiology of rare diseases whose onset will inevitably occur by coincidence following SARS ...

Source from : Medscape - 4 days ago


Europe Anticoagulant Reversal Drug Market Report 2021-2027: Market Opportunities with Increasing Research Activities on Anticoagulant Reversal Drugs

Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Europe Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product; End User" report has been added to ...

Source from : Yahoo Finance - 13 days ago